Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 14,230
-280 (-1.93%)
Apr 29, 2026, 1:10 PM KST
Hyundai Bioscience Revenue
In the year 2025, Hyundai Bioscience had annual revenue of 3.52B KRW, down -76.63%.
Revenue
3.52B
Revenue Growth
-76.63%
P/S Ratio
398.09
Revenue / Employee
50.98M
Employees
69
Market Cap
1,400.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.52B | -11.53B | -76.63% |
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,814.00B |
| Celltrion | 4,162.50B |
| ALTEOGEN | 215.86B |
| Samsung Epis Holdings | 1,510.14B |
| L&C BIO Co.,LTD | 85.48B |
| Chabiotech | 1,268.25B |
| GC Biopharma | 1,991.28B |
| HK inno.N | 839.63B |